• 10 JUL 2017
    • 0

    PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors

    LAGUNA HILLS, Calif., July 10, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr. Michael M. Abecassis to its Board of Directors. Dr. Abecassis is a renowned transplantation surgeon

    Read more →
    • 06 JUL 2017
    • 0

    PharmaCyte Biotech Releases Presentation to Oncologists and Interviews from 2017 ASCO Meeting Event

    LAGUNA HILLS, Calif., July 06, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the release of 3 videos from the company’s presentation and discussion with oncologists who attended this year’s annual meeting

    Read more →
    • 13 JUN 2017
    • 0

    PharmaCyte Biotech to Present Pancreatic Cancer Therapy at 2017 BIO International Convention

    LAGUNA HILLS, Calif., June 13, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s therapy for pancreatic cancer at the 2017 BIO

    Read more →
    • 09 JUN 2017
    • 0

    PharmaCyte Biotech Updates Shareholders on ASCO Presentation to Oncologists

    LAGUNA HILLS, Calif., June 09, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided an update from the company’s meeting with leading clinical oncologists who are interested in participating in PharmaCyte’s planned pivotal

    Read more →
    • 31 MAY 2017
    • 0

    PharmaCyte Biotech to Attend 53rd Annual Meeting of the American Society of Clinical Oncology

    LAGUNA HILLS, Calif., May 31, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its senior management team will attend the 53rd annual meeting of the American Society of Clinical Oncology (ASCO)

    Read more →
    • 08 MAY 2017
    • 0

    PharmaCyte Biotech Updates IND Submission Process in Interview with Facet Life Sciences

    LAGUNA HILLS, Calif., May 08, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released an educational, interview-style Q&A article with Sarah DeMare, the Product Development Champion with Facet Life Sciences and U.S. Agent

    Read more →
    • 02 MAY 2017
    • 0

    PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors

    LAGUNA HILLS, Calif., May 02, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Thomas Yuen to its Board of Directors. Mr. Yuen’s stellar career is exemplified by his global

    Read more →
    • 19 APR 2017
    • 0

    PharmaCyte Biotech Receives the 2017 “Pipelines of Promise” Award from BIO International

    LAGUNA HILLS, CA, April 19, 2017 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the 2017 Buzz of BIO “Pipelines of Promise” award ahead of the 2017 BIO

    Read more →
    • 18 APR 2017
    • 0

    PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director

    LAGUNA HILLS, Calif., April 18, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today an interview-style Q&A article that discusses the company’s Cannabis Research Program with Mark L. Rabe, MD, the Director of

    Read more →
    • 10 APR 2017
    • 0

    PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations

    LAGUNA HILLS, Calif., April 10, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has made significant progress with PharmaCyte’s Cannabis Research Program.

    Read more →